Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 5735 results for technology

  1. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

  2. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)

    This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.

  3. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab (Gazyvaro) for untreated chronic lymphocytic leukaemia in adults.

  4. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

    Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.

  5. Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee (TA508)

    Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.

  6. Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]

    Awaiting development Reference number: GID-TA10519 Expected publication date: TBC

  7. Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID6235]

    In development Reference number: GID-TA11246 Expected publication date:  05 March 2026

  8. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

  9. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

  10. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date:  25 February 2026

  11. Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer (TA1110)

    Evidence-based recommendations on abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.

  12. Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)

    Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.

  13. Bupivacaine–meloxicam for treating postoperative pain [ID2728]

    Awaiting development Reference number: GID-TA10716 Expected publication date: TBC

  14. Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)

    Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years.

  15. Adalimumab for treating moderate to severe plaque psoriasis (TA146)

    Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.